论文部分内容阅读
目的:测定合用低分子肝素钙对脑梗死患者依达拉奉血药浓度的影响。方法:对30例脑梗死的患者,分为2组,每组15例,单药组给予依达拉奉30 mg,静脉注射,bid,连用14 d;联合组依达拉奉用法用量与单药组一致,同时加用低分子肝素钙5 000 U,皮下注射,q12 h,连用5 d。两组患者在给药后的第1天和第5天的0,1,2,4,8,12,24 h抽取静脉血0.4 mL,利用高效液相色谱法测定依达拉奉血药浓度,同时记录两组不良反应情况。结果:联合组依达拉奉血药浓度显著高于单药组(P<0.05)。结论:合用低分子肝素钙对脑梗死患者体内依达拉奉血药浓度存在显著影响,能显著升高其体内浓度,增加不良反应的发生的可能性的可能性。
Objective: To determine the effect of combined low molecular weight heparin calcium on the plasma concentration of edaravone in patients with cerebral infarction. Methods: Thirty patients with cerebral infarction were divided into two groups (n = 15 each). Edaravone (30 mg) was given to the single drug group for intravenous injection for 14 days. The combined dosage of edaravone and single The same medicine group, while adding low molecular weight heparin calcium 5000, subcutaneous injection, q12 h, once every 5 d. Two groups of patients after administration of the first day and the fifth day of 0,1,2,4,8,12,24 h drawn venous blood 0.4 mL, determination of edaravone by high performance liquid chromatography , While recording two groups of adverse reactions. Results: The concentration of Edaravone in the combined group was significantly higher than that in the single drug group (P <0.05). Conclusion: The combination of low molecular weight heparin with Edaravone in patients with cerebral infarction has significant effect on the plasma concentration, which can significantly increase its concentration in vivo and increase the possibility of adverse reactions.